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Abstract: Depression is found in about 30%–40% of all patients with Parkinson’s disease (PD), 
but only a small percentage (about 20%) receive treatment. As a consequence, many PD patients 
suffer with reduced health-related quality of life. To address quality of life in depressed PD 
patients, we reviewed the literature on the health correlates of depression in PD (eg, cognitive 
function), etiology of depression in PD, and treatment options (ie, antidepressants, electrocon-
vulsive therapy, and psychotherapy). The current review is unique in its focus on psychosocial 
aspects, as well as neuropathological factors, of depression in PD. Overall, we conclude that 
neurochemical (eg, serotonin) and psychosocial factors (eg, coping style, self-esteem, and social 
support) contribute to the affective disturbances found in this neuropsychiatric population. 
Therefore, we recommend that a multidisciplinary (eg, pharmacotherapeutic, psychoeducational, 
and/or psychotherapeutic) approach to treatment be taken with depressed PD patients.
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Parkinson’s disease (PD) is a neurodegenerative disorder caused by the loss of 
dopaminergic neurons in the midbrain, which results in dysfunction of the nigrostriatal 
system producing alterations in movement such as tremor, bradykinesia, rigidity, 
and postural abnormalities. PD is generally characterized as a movement disorder, 
but depression occurs frequently in this population with a prevalence estimated 
at 30%–40% (Cummings 1992; Slaughter et al 2001; Zgaljardic et al 2003). 
Unfortunately, however, only 20% of all depressed PD patients receive treatment 
for their psychological status (Mayeux et al 1986; Huber et al 1988; Starkstein et al 
1990). If depression is left untreated, there is an increased risk for greater disability 
and reduced quality of life (Edwards et al 2002).
One reason why depression is undertreated in PD is due to the patient’s 
overshadowing concern for his/her physical relative to psychological health. Brod 
and colleagues (1998) have provided some evidence for this notion by observing 
that only 11% of depressed PD patients rated their psychological condition as a 
concerning health problem even though a majority of them were depressed. Similarly, 
depression failed to rank as one of the 20 most bothersome symptoms experienced by 
depressed PD patients (Scott et al 2000). Thus, even when PD patients are suffering 
from affective disturbances, they are more likely to complain about the burden of 
their motor disability. Therefore, physicians should regularly screen for depression 
when treating PD patients. However, it is often a difﬁ  cult diagnosis as many of the 
cognitive (eg, decreased concentration), motor (eg, agitation and decreased facial 
expression), and somatic (eg, decreased energy and disturbed sleep) features of PD 
and depression overlap (Edwards et al 2002).
Treatment is also complicated by the lack of reliable and valid instruments for 
assessing depression in patients with PD (Edwards et al 2002). For instance, rating Neuropsychiatric Disease and Treatment 2008:4(1) 82
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scales, such as the Beck Depression Inventory (BDI) (Beck 
et al 1961) and Hamilton Depression Rating Scale (HDRS) 
(Hamilton 1960), may over-diagnose depression in PD 
because the source of the somatic items could be inﬂ  uenced 
by parkinsonian symptoms (Leentjens et al 2000). However, 
the BDI and HDRS were tested for their diagnostic accuracy 
for depression in PD (Leentjens, Verhey, Lousberg et al 
2000; Leentjens, Verhey, Luijckx et al 2000), and both scales 
showed adequate sensitivity (BDI = 67%, and HDRS = 83%) 
and speciﬁ  city (BDI = 88%, and HDRS = 95%). Conversely, 
DSM-IV criteria are the most widely accepted method of 
evaluating depression in PD (Zesiewicsz et al 1999), but 
require a trained administrator and may take a signiﬁ  cant 
amount of time to administer. Because it is easier to evaluate 
depression with the BDI than with DSM-IV criteria or the 
HDRS, the BDI should be considered as the preferred method 
for screening depression in PD. However, future research 
should assess the geriatric depression scale (Yesavage et al 
1982) for its diagnostic accuracy in PD because it may 
provide better control for the somatic complaints that are 
associated with age and disease severity in PD.
Even when a diagnosis of depression is made accurately, 
it is not clear which treatment options (eg, psychotherapy or 
pharmacotherapy) are safe and effective for this population. 
Thus, in this article, we review the health risks, etiological 
factors, and treatment options for depression in PD towards 
improving health-related quality of life in PD patients 
suffering from depression. The current review is unique in 
its focus on psychosocial aspects, as well as neuropathologi-
cal factors, of depression in PD.
Depression and associated health 
risks in PD
Depression and cognition
Cognitive deﬁ  cits are common even in non-depressed and 
non-demented PD patients (for reviews, see Raskin et al 1990; 
Morrison et al 2000). However, certain aspects of cognition are 
more severely impaired in depressed PD patients (for reviews, 
see Emre 2003; Zgaljardic et al 2003). Unfortunately, these 
impairments can place depressed patients with PD at greater 
risk for developing dementia (Dalrymple-Alford et al 1994; 
Lombardi et al 2001). Dementia constitutes a negative health 
outcome in PD because it is associated with greater functional 
disability and institutionalization in nursing homes (Emre 
2003). Moreover, mortality rates are higher for demented 
than non-demented PD patients (Mindham et al 1982). Thus, 
identiﬁ  cation and treatment of PD patients with depression 
may prevent subsequent cognitive and functional decline.
Executive dysfunction is the type of cognitive impairment 
most closely related to the development of dementia in PD 
(Levy et al 2002). Indeed, depressed patients with PD have 
signiﬁ  cantly greater impairments in attention and working 
memory (Uekermann et al 2003) and perform more poorly on 
neuropsychological measures of frontal/executive function 
(ie, Wisconsin Card Sorting Test and Raven Progressive 
Matrices) than non-depressed patients with PD (Kuzis 
et al 1997). Other studies have bolstered these ﬁ  ndings in 
showing that depression at baseline increases the risk for 
developing dementia later in PD (Starkstein et al 1990; 
Stern et al 1993; Hughes et al 2000). Indeed, PD patients 
who were treated for depression evidenced less cognitive 
decline over a 3–4 year period relative to those who were not 
(Kremer and Starkstein 2000). The extent to which cognitive 
decline contributes to depression could help to understand 
functional disability and health-related quality of life in PD. 
Thus, treating depression in PD may help to prevent or delay 
the progression of cognitive and functional decline in this 
neuropsychiatric population.
Depression and health-related quality 
of life
The term health-related quality of life (HRQL) has been used 
to describe the distress and functional impairment produced 
by a chronic debilitating illness.1 Overall, research using 
generic and disease-speciﬁ  c scales has found motor disabil-
ity to be an obvious and important determinant of reduced 
HQRL in PD (Peto et al 1995; Dodel et al 2001; Keranen 
et al 2003). However, there is also a growing literature that 
shows that even beyond motor disability, depression can be 
a risk factor for reduced HRQL in PD (Karlsen et al 1995; 
Hobson et al 1999; Schrag et al 2001).
Karlsen et al (1999) used the Nottingham Health Proﬁ  le 
(NHP) to determine which clinical features reduce HRQL 
in PD. A generic quality of life questionnaire, the NHP, 
measures six dimensions – emotional reactions, energy, pain, 
physical mobility, sleep, and social isolation (Jenkinson et al 
1988). Overall, depression was related to negative emotional 
reactions, low energy, pain, and social isolation but not to 
physical mobility problems and sleep disorders (Karlsen 
et al 1999). Nonetheless, other studies using PD-speciﬁ  c 
measures of HRQL have found a relationship between 
depression and these health outcomes (Hobson et al 1999; 
Schrag et al 2001).
One study that used a PD specific scale on HRQL 
(ie, PDQ-39) observed that depression was significantly 
associated with poorer quality of life in this population (Schrag Neuropsychiatric Disease and Treatment 2008:4(1) 83
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et al 2001). Brieﬂ  y, the PDQ-39 is a PD-speciﬁ  c, HRQL 
questionnaire that consists of eight health dimensions – mobility, 
activities of daily living, emotional well-being, stigma, social 
support, cognition, communication, and bodily discomfort 
(Peto et al 1995). Overall, depressed PD patients scored sig-
niﬁ  cantly lower than non-depressed PD patients on all eight 
dimensions of the PDQ-39, particularly on items that tapped 
emotional well-being and cognition. Furthermore, after con-
trolling for motor disability severity, depression signiﬁ  cantly 
predicted all areas of HRQL on the PDQ-39.
Additional evidence deriving from another disease-
speciﬁ  c scale has offered greater reliability to the notion that 
depression is a serious risk factor for reduced HRQL found 
in PD. De Boer and colleagues (1996) developed the PD 
Quality of Life Questionnaire (PDQL) to determine which 
clinical and demographic variables are related to HRQL in 
PD. It assesses four dimensions of health – parkinsonism, 
systemic symptoms, social functioning, and emotional 
functioning. Again, depression was the best predictor of 
poor HRQL along all four dimensions of the PDQL relative 
to age, disease severity, and cognitive impairment (Hobson 
et al 1999). Further, depression produced the poorest scores 
on the parkinsonian and emotional functioning subscales of 
the PDQL (Hobson et al 1999).
The studies (reviewed above) using the PDQ-39 and 
PDQL produced convergent results that depression predicted 
reduced HRQL (Hobson et al 1999; Schrag et al 2001). In a 
recent paper on the psychometric properties of the PDQ-39 
and PDQL (Marinus et al 2002), the PDQ-39 was deemed the 
most appropriate instrument for measuring HRQL “because 
it has been tested most thoroughly, has adequate clinimet-
ric characteristics, has been used in the largest number of 
studies, and is available in many languages” (p 248). Thus, 
the PDQ-39 can be adopted as an instrument for studying 
depression and HRQL in PD.
Depression should be considered a risk factor for poor 
HRQL in PD, thus, it is conjectured that HRQL, cognitive 
function, and emotional-well-being would potentially 
improve once depression is alleviated in PD. However, what 
is not clear are the factors that contribute to depression in PD 
and which treatment options are safe and effective for use in 
this neuropsychiatric population.
Etiology of depression in PD
There have been several explanations for why depres-
sion occurs in PD. A psychological explanation suggests 
that depression is a reaction to the stress of coping with a 
chronic and progressively disabling disease. A biomedical 
perspective argues that depression is a primary neurochemical 
consequence of the neurodegenerative process of PD, 
attributing depression in PD to deﬁ  cits in dopaminergic, 
noradrenergic, and/or serotonergic systems (Hornykiewicz 
1982; Cummings 1993). Evidence from studies that have 
examined disease correlates (eg, motor severity, duration, 
and functional disability) of PD, prevalence rates, and brain 
abnormalities between depressed and non-depressed PD 
patients have supported both models and are described 
below.
Correlates of depression within PD
According to the psychological-reactivity model, it is 
hypothesized that depression will be positively correlated 
with severity, duration, and disability factors in PD. Studies 
examining these correlates of depression in PD have not 
provided consistent evidence for the psychological-reac-
tivity model. For instance, studies that have examined PD 
disease duration and depression did not ﬁ  nd a signiﬁ  cant 
relation between the two variables (Warburton 1967; 
Celesia and Wannamaker 1972; Lesser et al 1979; Mayeux 
et al 1981,1984; Dakof and Mendelsohn 1989; MacCarthy 
and Brown 1989; Schrag et al 2001). Whereas some stud-
ies found a signiﬁ  cant relationship between PD severity 
and depression (Hoehn et al 1976; Mindham et al 1976; 
Singer 1976; Gotham et al 1986; Dakoff and Mendelsohn 
1989; Fleminger 1991; Schrag et al 2001), others have not 
(Warburton 1967; Celesia and Wannamaker 1972; Mayeux 
et al 1981; Mayeux 1984; Huber et al 1988; MacCarthy 
Brown 1989).
Findings relating depression to functional disability are 
also inconsistent. For instance, several studies have found that 
depression is signiﬁ  cantly and positively correlated with dis-
ability in PD (Gotham et al 1986; Brown et al 1988; Ehman 
et al 1990; Menza and Mark 1994; Tandberg et al 1997; 
Schrag et al 2001). However, depression does not improve 
in PD patients once disability is reduced following levodopa 
therapy (Goodwin et al 1970; Cheifetz et al 1971; Marsh and 
Markhan 1973; Hoehn et al 1976; Lesser et al 1979; Mayeux 
et al 1981). Therefore, conﬂ  icting results do not provide a 
clear indication that depression is simply a reaction to the 
disabling aspects of PD.
Biomedical perspective and brain imaging
One aspect of the biomedical model argues that depression 
may be a sequela of changed brain chemistry that is separate 
from the dopaminergic deﬁ  ciency associated with PD motor 
symptoms (Marsh and Markham 1973; Mayeux 1984; Mayeux Neuropsychiatric Disease and Treatment 2008:4(1) 84
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et al 1984). This premise is based on the observation that 
levels of cerebrospinal ﬂ  uid 5-HIAA, a metabolite of serotonin 
(5-HT), are reduced in depressed PD patients (Mayeux et al 
1984, 1986). Initially, critics of this hypothesis reported that 
even non-depressed PD patients showed metabolite reductions 
(Kostic et al 1987), suggesting that either CSF metabolites 
were inaccurate measures of changes in brain 5-HT or that 
depressed PD patients were not qualitatively different from 
non-depressed PD patients. More recent neuroimagining 
and neuropharmacological research has been used to better 
understand the biological etiology of PD depression.
Neuroanatomical differences between depressed and 
non-depressed PD patients have been studied (Mayberg et al 
1990; Mayberg and Solomon 1995; Sagar 1999). Depressed 
PD patients show metabolic abnormalities during PET 
scans in both the caudate and inferior frontal cortices as 
compared to non-depressed PD patients and aged-matched 
healthy controls (Mayberg et al 1990). PET studies have also 
shown lower metabolic activity in the prefrontal cortex in 
depressed relative to non-depressed PD patients (Paulus and 
Trenkwalder 1998). Though these studies point to a biologi-
cal etiology of PD depression, one criticism is that while 
depressed and non-depressed PD patients are compared, 
these studies do not directly compare depressed PD patients 
to non-neurologically ill depressed patients. This leaves open 
the possibility that depression alone could also contribute to 
metabolic deﬁ  cits, rather than the effect of PD.
Evidence from non-neurologically depressed patients 
has shown metabolic abnormalities in the same area of the 
brain (ie, prefrontal cortex) that is also affected in depressed 
patients with PD (Rubin et al 1994; Brody et al 2001; Martin 
et al 2001). Moreover, psychotherapy is useful in reducing 
depression and in increasing metabolic activity (assessed 
through PET) in the frontal cortex, temporal lobe, basal 
ganglia, and cingulate gyrus in non-neurological depressed 
patients (Martin et al 2001). Thus, there is a potential con-
tribution of psychosocial factors to neuroanatomical differ-
ences observed between depressed and non-depressed PD 
patients (Mayberg et al 1990; Mayberg and Solomon 1995; 
Sagar 1999). The differentiation of abnormalities among 
depressed PD patients, non-depressed PD patients, and non-
neurologically ill patients with depression has to be made, 
and understood in the context of structural neuroanatomy, 
metabolic activity, and therapeutic treatment response.
Depression in PD versus other illnesses
Whether depression is found more frequently in PD rela-
tive to other non-neurological illnesses is unclear. If PD 
patients are at greater risk for developing depression, then 
the affective disturbances found in PD can be related to 
neurological disease as opposed to a psychosocial stress 
response in reaction to having a chronic and disabling illness. 
Several studies examined rates of depression between PD 
patients and other disabled clinical populations. Again, the 
collective evidence does not support either a biomedical or 
psychological interpretation. For instance, three separate 
studies found that PD patients were significantly more 
depressed than paraplegics, amputees, and patients suffering 
from various medical/surgical conditions (Wartburton 1967; 
Horn 1974; Robins 1976). However, the comparison groups 
in these studies were not equivalent to the PD sample with 
respect to age and duration of illness.
Ehman et al (1990) compared levels of depression 
between patients with PD and rheumatoid arthritis (RA), and 
observed that depression was higher for the PD group. This 
ﬁ  nding could suggest that depression in PD may be caused 
by endogenous factors rather than a psychological reaction to 
coping with a physically debilitating disorder. However, the 
two groups were different with respect to disease duration, 
with the PD group duration lasting 3.5 years whereas the 
RA group was ill for over 14 years. Given that other studies 
have shown that psychological disturbances tend to occur 
more frequently in the early stages of chronic illness because 
the patient has not yet learned how to cope effectively with 
their disease (Meyerowitz 1980), the greater rates of depres-
sion found in PD relative to RA patients (Ehman et al 1990) 
may be attributed to the PD patients not having enough time 
to develop a more adaptive means of coping with their illness. 
Singer (1976) suggested that the longer PD patients have the 
disease, the more stoically they accept their symptoms. Thus, 
an important variable that may distinguish depressed from 
non-depressed PD patients is how the individual copes with 
their chronic illness over time (Brown et al 1988).
Psychosocial reactivity and depression
Psychosocial variables, such as coping style and amount of 
social support, may predict depression more reliably than 
severity, illness duration, and functional disability (Brown 
and McCarthy 1989; Dakoff and Mendelson 1989; Ehman 
et al 1990; Frazier 2000). For instance, Brown and McCarthy 
(1989) examined the inﬂ  uence of psychosocial variables in 
predicting depression in PD patients. Overall, the best predic-
tors of depression were functional disability, low self-esteem, 
and avoidant coping. These variables accounted for 46% of the 
variance in depression. Furthermore, positive affect and cog-
nitive coping (eg, acceptance of illness) signiﬁ  cantly predicted Neuropsychiatric Disease and Treatment 2008:4(1) 85
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lower depression. This study found that disease-related 
variables (eg, severity and functional disability) do not pre-
dict a large portion of the variance in the depression that is 
experienced in PD. The observed inconsistent ﬁ  ndings suggest 
that the reactivity model is in need of revision and should also 
include psychosocial variables (Dakoff and Mendelson 1989; 
Ehman et al 1990; Frazier 2000).
Evidence supports the notion that psychosocial factors 
reliably predict depression in PD (Ehman et al 1990). After 
controlling for functional disability, PD patients were 
signiﬁ  cantly more depressed than RA patients. Again, this 
ﬁ  nding could be interpreted as evidence for the biological 
model of depression in PD. However, coping style was also 
examined; the RA group used signiﬁ  cantly more cognitive 
coping strategies in dealing with their disease than the PD 
group. Instead, the PD group used more avoidant coping 
to manage their disease. Interestingly, when PD patients 
utilized cognitive coping strategies, there were signiﬁ  cant 
reductions in depression, improvements in disability, and 
more frequent engagements in socialization. Thus, this 
study found that disease-related variables (eg, functional 
disability) are not sufﬁ  cient for a clear picture of the etiology 
of PD depression and that psychosocial variables, such as 
coping style, are important in understanding the reactive 
nature of depression in PD.
One important question that can be raised from the above 
psychosocial literature is whether PD patients, who may 
perseverate or lack the ability to be ﬂ  exible, have difﬁ  culty 
adopting more malleable coping styles. Relevant to this 
question, research shows that PD patients have a tendency to 
maintain stable coping patterns across the trajectory of their 
illness even when such strategies lead to poor mental and 
physical health outcomes (Frazier 2002). For instance, the 
majority of PD patients continued to use maladaptive coping 
strategies (eg, active coping for physical stressors) rather 
than shift to adaptive coping strategies (eg, emotion-regula-
tion coping) in the face of progressing motor and functional 
disability (Frazier 2002). Although it was less common, PD 
patients who displayed ﬂ  exibility in coping strategies over 
time evidenced better health outcomes. Thus, PD patients, on 
the whole, may beneﬁ  t from a psychosocial intervention that 
educates them on utilizing appropriate coping strategies for 
various stressors associated with the progressive and unpre-
dictable nature of PD. Additionally, because the majority of 
PD patients utilized stable and inﬂ  exible (ie, dispositional) 
coping strategies, research directed toward differentiating PD 
from other movement disorders and other non-neurologically 
ill populations (eg, rheumatoid arthritis) could be conducted. 
These comparisons would directly test whether PD patients 
by nature of their neurological disease have a particular 
coping style that contributes to their depression.
In summary, as evidence does not permit discrete choice 
between the biomedical or psychological position with 
respect to the etiology of PD depression, a more parsimonious 
perspective should include a combination of endogenous 
(neurochemically based) and exogenous (environmental) 
factors (eg, Poewe and Seppi 2001). Therefore, we further 
examined the literature on treatment options for PD 
depression to understand its etiology towards improving 
quality of life for this neuropsychiatric population.
Treatment options for depression 
in PD
Tricyclic antidepressants
Depression in PD has been treated effectively with tricyclic 
antidepressants (TCAs). Early work prior to L-dopa use may 
not be comparable to research after its introduction in 1975. 
Strang (1965) conducted a double-blind study on the effects of 
imipramine (150–250 mg/day) in PD and found that depression 
improved for 60% of the patients. Moreover, this study found 
that antidepressant therapy had a beneﬁ  cial effect on rigidity, 
tremors, and akinesia. Supportive studies showed that motor 
deﬁ  cits and depression were improved using a double-blind 
study on the effects of desipramine (100 mg/day) in PD: reduc-
tions in rigidity and tremors were evident in patients whose 
depression responded favorably to antidepressants (Laitnen 
1969). These results suggest that TCAs can be used effectively 
for treating both depression and motor disability in PD. The 
association between depression and motor improvement is that 
imipramine (Strang 1965) and desipramine (Laitnen 1969), as 
well as nortriptyline (Anderson et al 1980) and amitriptyline 
(Indaco and Carrieri 1988), block the reuptake of norepineph-
rine (Maxmen and Ward 1995). The mechanism for TCAs on 
norepinephrine (NE) is important because of the link of NE to 
parkinsonian symptoms and to dopamine (DA) levels within the 
basal ganglia, and the progressive loss of noradrenergic neurons 
in the locus coeruleus of PD patients (Gesi et al 2000). Animal 
models of PD show that drugs that increase the concentration 
of NE in the locus coeruleus (eg, 2-methoxy idazoxan) also 
reduce parkinsonian symptoms and increase DA levels in the 
basal ganglia of rats (Srinivasan and Schmidt 2003, 2004). In 
terms of depression, TCAs also block 5-HT reuptake in the 
raphe system and frontal cortex (Bel and Artigas 1996). There-
fore, TCAs can improve motor and affective function in PD by 
blocking NE reuptake in two distinct pathways (ie, nigrostriatal 
[DA] and raphe [5-HT] systems).Neuropsychiatric Disease and Treatment 2008:4(1) 86
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Whereas TCAs may be useful in treating depression and 
motor functioning (Strang 1965; Laitinen 1969; Andersen 
et al 1980), many patients cannot tolerate them although 
some side effects of the TCAs in lower doses are used to 
treat excess salivation and sleep derangement in PD patients. 
Adverse effects of TCAs include cardiac arrhythmias, ortho-
static hypotension, fatigue, and memory impairment. At 
high doses, TCAs can produce confusional states, seizures, 
and delirium in depressed PD patients. Because selective 
serotonin reuptake inhibitors (SSRIs) have a lower side 
effect proﬁ  le in patients without PD, physicians have more 
recently been prescribing SSRIs over TCAs for depressed PD 
patients (Richard and Kurlan 1997). However, it is important 
to note that the safety and efﬁ  cacy of SSRIs have not been 
established for depressed PD patients.
Serrotonin re-uptake inhibitors
There have been several clinical trials examining the effects 
of SSRIs in PD. Hauser and Zesiewicz (1997) conducted a 
7-week open-label trial that examined the effects of sertraline 
(25–50 mg/d) in 15 depressed PD patients. Overall, there was 
a signiﬁ  cant decrease in depression levels between baseline 
and post-testing. Unlike the TCA studies described above, 
sertraline did not improve motor performance measured 
by the Uniﬁ  ed Parkinson’s Disease Rating Scale (UPDRS) 
(Fahn et al 1987). There have also been two open-labeled 
clinical trials examining the effects of paroxetine for depres-
sion in PD. Once again, these studies found that SSRIs were 
able to reduce depression, but there was also evidence of a 
deterioration of motor symptoms in many of the PD patients 
(Ceravolo et al 2000; Tesei et al 2000). Thus, SSRIs can be 
effective in treating depression in PD but without the salutary 
beneﬁ  ts that were seen with TCAs on motor functioning 
(Strang 1965; Laitinen 1969; Anderson et al 1980; Goetz 
et al 1984; Klaasen et al 1995) or even an increase in motor 
symptoms. The question remains as to whether or not SSRIs 
can exacerbate parkinsonian symptoms.
Research regarding the use of SSRIs in PD shows dete-
rioration in motor symptoms in some studies (Steur 1993; 
Jimenez et al 1994; Ceravolo et al 2000), while not in others 
(Caley and Friedman 1992; Montastruc et al 1995; Hauser 
and Zesiewicz 1997). These studies used low constraint 
research methods (ie, case reports and open-label trials). More 
recent placebo-controlled trials have assessed the effects of 
SSRIs on depressive and motor symptoms in PD (Wermuth 
et al 1998; Rampello et al 2002; Leenjens et al 2003). 
Wermuth et al (1998) conducted a placebo-controlled trial 
on PD patients suffering from major depression. The SSRI 
citalopram or placebo was administered to an average of 10 
subjects in each group over the course of 52 weeks. There 
were no signiﬁ  cant group differences on measures of depres-
sion (ie, HDRS), motor function (ie, UPDRS), or adverse side 
effects (UKU Side Effects Scale; Lingjaerde et al 1987). Of 
note, at study outset, 60% of the sample consisted of patients 
with severe recurrent brief depression, which lasted for 2–3 
days. Perhaps a treatment effect was not observed because 
depression would have subsided in the majority of patients 
after several days. Thus, this randomized placebo-controlled 
trial can be criticized for containing sampling error. Leentjens 
et al (2003) also conducted a study using the SSRI citalopram 
(n = 6) or placebo (n = 4) on severely depressed PD patients. 
Once again, there were no signiﬁ  cant group differences in 
measures of depression (ie, Montgomery-Asberg Depression 
Rating Scale (MADRS)) (Montgomery and Asberg 1979) or 
motor function (ie, UPDRS). Because this study contained 
only 12 severely depressed PD patients, the non-signiﬁ  cant 
ﬁ  ndings could have been due to lack of statistical power.
Rampello et al (2002) observed that citalopram improved 
motor performance (ie, bradykinesia and ﬁ  nger tapping 
speed) for both depressed (n = 18) and non-depressed 
(n = 14) PD patients relative to a non-depressed placebo 
(n = 14) control group. Depression was signiﬁ  cantly reduced 
for the depressed PD subgroup. The researchers argued that 
improvements in depression and motor function occurred 
because of the ability of SSRIs to enhance mesolimbic sero-
tonin levels and to simultaneously reinforce dopaminergic 
release in cell bodies of the nigrostriatal system via 5-HT2a 
and 5-HT4 postsynaptic and/or 5-HT3 presynaptic receptors. 
These ﬁ  ndings support the biological basis of depression in 
PD (Hornykiewicz 1982; Cummings 1993) and that SSRIs, 
such as citalopram, might provide salutary health beneﬁ  ts to 
depressed and non-depressed PD patients.
Monoamine-oxidase inhibitors
The biomedical approach has attributed PD-related depres-
sion to a deﬁ  cit in dopaminergic (Mayeux 1992), norad-
renergic (Hornykiewicz 1982), and serotonergic brainstem 
ascending systems (Hornykiewicz 1982; Mayeux et al 1984). 
As a result, inhibition of monoamine oxidase (MAO) does 
not seem like an unreasonable approach to the treatment 
of PD depression. The two forms of MAO inhibitors were 
relevant, MAO-A (selective for noradrenaline and serotonin 
metabolism for treatment of depression) and MAO-B (selec-
tive for DA and used in PD treatment), especially early on 
to postpone progression of disease. If used in high doses, 
MAO-B inhibitors will be active for A and B pathways.Neuropsychiatric Disease and Treatment 2008:4(1) 87
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When selegiline is dosed at 10 mg a day or less in PD, 
it can serve as an irreversible inhibitor of brain MAO-B 
enzyme. Accordingly, selegiline at 10 mg a day may increase 
DA levels, which in turn can improve motor function in PD 
patients (Parkinson Study Group 1993). Thus, selegiline, at its 
usual clinical dose, should not exert an antidepressant effect 
because it selectively inhibits MAO-B (and not MAO-A) 
enzymes in the adult human brain. However, selegiline was 
initially introduced as an antidepressant because the drug 
can also act as an MAO-A inhibitor when given at slightly 
higher doses (Sunderland et al 1985).
Quitkin and colleagues (1984) tested the effects of sele-
giline (20 mg/day) on 17 atypical depressives without PD 
and found that improvement occurred in 60% of the patients. 
Mann et al (1989) conducted a double-blind placebo-
controlled trial testing the effects of selegiline on patients suf-
fering from primary depression. Depression was signiﬁ  cantly 
reduced in patients assigned to the selegiline group relative 
to those assigned to the placebo control group. Additionally, 
signiﬁ  cantly greater reduction of depression scores occurred 
with higher ( 30 mg) than with lower ( 30 mg) doses of 
selegiline. A more recent placebo-controlled trial revealed 
that transdermal selegiline (20 mg/day) administered for 
6 weeks was an effective and well-tolerated treatment for 177 
adult outpatients suffering from major depression (Bodkin 
and Amsterdam, 2002). Therefore, selegiline could serve as 
an efﬁ  cacious antidepressant at higher doses in depressed 
patients with PD. However, its use at higher doses in PD is 
sparse, and the focus of selegiline research has been restricted 
to MAO-B inhibition.
Dopamine replacement
Some literature implicates DA agonist’s utility in the treat-
ment of depression. For instance, D2/D3 agonists (eg, 
pramipexole and pergolide) have reduced depression in 
non-neurologically ill patients and improved motor function 
in PD patients (Corrigan et al 2000; Reichmann et al 2003; 
Rektorova et al 2003). To date, there have been no known 
studies examining the effects of dopaminergic antidepressants 
(eg, buproprion or velaxeﬁ  ne) in PD. Because DA agonists 
have been shown to reduce depression and improve motor 
function in PD, more research is needed to examine whether 
selegiline and dopaminergic antidepressants can serve as both 
antidepressant and antiparkinsonian agents in PD.
A meta-analysis conducted in Parkinson’s disease 
(Weintraub et al 2005) examined the effects of antidepres-
sants on PD-related depression and obtained a large effect 
size for depression outcomes in both the antidepressant 
(d = 1.34) and placebo control group (d = 1.19). Further, the 
researchers did not observe a signiﬁ  cant between-group dif-
ference, Qb(1) = 0.43, p = 0.51. They concluded that antide-
pressant treatment has a “non-speciﬁ  c” effect on depression 
in PD, which may be confounded because the effect size data 
from their control group was derived only from two SSRI 
studies that possibly contained sampling error (Wermuth 
et al 1998; Leenjens et al 2003). Moreover, the researchers 
excluded the TCA antidepressant class from their analysis 
which may have further limited their ability to detect a signiﬁ  -
cant treatment effect between the antidepressant and placebo 
groups. As TCAs can be effective in treating depression and 
improving motor function in PD (Strang 1965; Laitnen 1969; 
Anderson et al 1980; Indaco and Carrieri 1988), physicians 
in clinical care might consider using TCAs for certain situ-
ations in depressed PD patients.
Electroconvulsive therapy
The potential beneﬁ  ts of electroconvulsive therapy (ECT) 
have been explored as a treatment modality for PD patients 
suffering from depression. A literature review conducted 
between 1975 and 1991 (Faber and Trimble 1991) provided 
evidence that depression can be reduced in most PD patients 
treated with ECT. Approximately 70% of PD patients 
showed improvement in psychiatric disturbances (includ-
ing depression) across the 21 studies reviewed. In another 
study conducted on 25 depressed PD patients, depression 
was significantly reduced following ECT (Moellentine 
et al 1998). ECT can serve as a viable treatment option for 
depressed PD patients as the electrically induced seizures can 
increase both norepinephrine and serotonin levels in the brain 
(Poewe and Seppi 2001). Because norepinephrine increases 
DA levels in the basal ganglia and reduces motor symptoms 
(Gesi et al 2000; Srinivasan and Schmidt 2003, 2004), both 
affective and motor functions may be improved in PD via 
ECT. In support of this notion, several studies have found 
that ECT improved motor symptoms (Douyone et al 1989; 
Friedman and Gordon 1992; Mollentine et al 1998; Strome 
et al 2007) and depressed mood in PD patients (Faber and 
Trimble 1991).
Although these positive outcomes seem to suggest that 
ECT can serve as an alternative treatment to antidepressant 
therapy, risks for developing side effects such as delirium 
(Moellentine et al 1998) can occur with ECT use in PD. 
ECT may not be a ﬁ  rst line therapy unless PD patients are 
self-destructive and/or non-responsive to drug therapy (Kim 
and Hershey 1988). The majority of depressed PD patients 
tend to suffer from mild to moderate depression and areNeuropsychiatric Disease and Treatment 2008:4(1) 88
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not suicidal (Slaughter et al 2001), so that safe and effective 
treatments still rely on pharmacological or behavioral 
treatments. Consequently, ECT is not appropriate for most 
PD patients.
Psychotherapy
Consensus among physicians and researchers posits that 
psychotherapy can be a helpful treatment modality for PD 
patients, in general, and especially for those individuals who 
are suffering from mild or moderate depression (Dakof and 
Mendelsohn 1986; Poewe and Luginger 1999; Kremmer 
and Starkstein 2000; Slaughter et al 2001). For instance, 
behavioral therapy around the time of PD diagnosis and 
during advancing stages of the illness can adequately con-
trol for mood disorders in many PD patients (Poewe and 
Luginger 1999). Brown and Jahanshashi (1995) suggested 
that a psychotherapy program should be adapted to each PD 
patient to prevent and treat the depression that is associated 
with the disease. These researchers further suggested that the 
program should focus on disability and handicaps produced 
by PD and should be continued throughout the course of the 
illness (Brown and Jahanshashi 1995).
Whereas the importance of psychotherapy appears to be 
well recognized by the medical community, surprisingly, 
a literature search of the Medline and Psych-Info abstract 
indices generated only two experimental studies on the effects 
of a behavioral-cognitive intervention of any kind for PD 
patients suffering from affective disturbances (Ellgring et al 
1993; Trend et al 2002). Ellgring et al (1993) systematically 
explored whether PD patients would respond favorably to 
a psychological intervention. Overall, counseling aimed at 
facilitating cognitive restructuring was able to reduce overall 
stress, improve social functioning, and increase acceptance of 
the illness. Whether this intervention would have improved 
depression, in particular, in this sample of PD patients is 
unclear because it was not assessed as a health outcome by 
the researchers (Ellgrig et al 1993).
Trend et al (2002) observed that depression scores were 
signiﬁ  cantly reduced for PD patients after receiving relaxation 
training and individual talks from a multidisciplinary team of 
therapists, including a PD nurse specialist, physiotherapist, occu-
pational therapist, speech therapist, and care manager, over a 
6-week period. Although improvements in mood at post-testing 
were noted, none of the patients could be classiﬁ  ed as depressed 
because of their low baseline scores on a non-validated measure 
of depression (ie, the Hospital Anxiety and Depression Scale) 
in PD. Therefore, the efﬁ  cacy of behavioral-cognitive therapy 
has yet to be established for depressed PD patients.
Conclusions
Delayed treatment of depression in PD will lead to reduced 
quality of life. We believe that a multidisciplinary (eg, 
pharmacotherapy, psychoeducational, and/or psychotherapy) 
approach to treatment should be assumed. Nonetheless, 
before PD patients can be treated, they need to be accu-
rately diagnosed with depression, and to reiterate, it is often 
difﬁ  cult to diagnose depression in this clinical population 
because many of the symptoms of PD and depression overlap 
(Edwards et al 2002). Programs of research that focus on the 
measurement of depression in PD are urgently needed so that 
more patients can be actively identiﬁ  ed and treated for their 
affective disturbances.
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Note
1Currently, there are several scales that are used to measure 
health-related quality of life in PD, both generic (non-speciﬁ  c 
to PD) and speciﬁ  c to PD (Bergner et al 1981; Jenkinson et al 
1988; Peto et al 1995).
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